医药生物行业动态研究:CRO需求回暖,实验猴供给紧张涨价
Guohai Securities·2025-12-22 08:18

Investment Rating - The report maintains a "Neutral" rating for the pharmaceutical and biotechnology industry [1][42]. Core Insights - There is a recovery in demand for clinical research organizations (CROs), while the supply of experimental monkeys is tight, leading to price increases. The domestic financing for innovative drugs is gradually recovering, with a total financing amount of $4.086 billion from January to November 2025, representing a year-on-year increase of 10.6% [1][10]. - The pharmaceutical sector has underperformed compared to the CSI 300 index, with a year-to-date return of 14.49% against the CSI 300's 16.09% [22]. - The current valuation of the pharmaceutical sector is 33.0 times PE based on 2026 profit forecasts, which is a 41% premium over the overall A-share market (excluding financials) [23]. Summary by Sections Recent Trends - The CSI 300 index fell by 0.28% this week, while the pharmaceutical sector decreased by 0.14%, ranking 22nd among 31 primary sub-industries. The weekly performance of sub-sectors includes declines in chemical pharmaceuticals and biological products, while medical services and medical commerce showed gains [9][22]. Market Dynamics - The demand for CROs is recovering, and the supply of experimental monkeys is limited, with prices for 3-5 year old monkeys reaching 140,000 yuan each. This indicates a recovery in the domestic innovative drug research and development environment [10][11]. Valuation - The pharmaceutical sector's current valuation is 29.1 times PE based on trailing twelve months (TTM) earnings, which is below the historical average of 35.0 times PE. The sector has a 17.2% premium over the overall A-share market [23]. Company Performance - Notable performers in the pharmaceutical commercial sector this week include Huaren Health, Luyuan Pharmaceutical, and Shuyuan Pingmin, with significant weekly gains [25]. Key Company Meetings - Upcoming shareholder meetings include Dong'e Ejiao, Zhonghe Holdings, and Yiling Pharmaceutical on December 22, among others [31][32][33].

医药生物行业动态研究:CRO需求回暖,实验猴供给紧张涨价 - Reportify